Joined January 2021
- Tweets 208
- Following 207
- Followers 251
- Likes 232
1 Photos and videos
12 Dec 2023
Research in Mustjoki Lab @hruh_research was carried out under the iCAN Digital Precision Cancer Medicine Flagship (@iCAN_Finland) & also supported by Research Council of Finland (@SuomenAkatemia), @Syopasaatio, Jane & Aatos Erkko Foundation, and @SigridJuselius
1
3
247
12 Dec 2023
Stay tuned for a “tweetorial” by @ollidufva, @DrSGandalf and colleagues for more details on main findings and key implications of this @ImmunityCP paper! @DanaFarber @hruh_research @iCAN_Finland @CellPressNews #mmsm #leukemia #lymphoma
3
249
12 Dec 2023
New collaborative paper by Mustjoki Lab (@hruh_research) & @CMitsiadesLab published @ImmunityCP. doi.org/10.1016/j.immuni.202…
Single-cell functional genomics of #NKcell #resistance in blood cancers
#immunotherapy #myeloma #mmsm #leukemia #lymphoma #CRISPR @DanaFarber @broadinstitute
4
10
37
11,398
12 Dec 2023
We are grateful at the @CMitsiadesLab for our funding sources that supported this study, including @NIHfunding, @theNCI, @LLSusa, @Ludwig_Cancer at Harvard, @VdeGunzburg, @SU2C, @Myeloma_Society, @LLslf, the Corman Family and Cobb Family
1
3
199
12 Dec 2023
This study provides a comprehensive landscape of molecular changes in NK and blood cancer cells when they interact and the mechanisms contributing to sensitivity vs #resistance to #NKcell-based therapies, providing a framework for new personalized therapies @ImmunityCP #ASH23
1
1
194
12 Dec 2023
Congratulations to @ollidufva & @DrSGandalf, who are co-first authors of this study at @ImmunityCP @CellPressNews. Many thanks to all colleagues & collaborators in this study
1
2
233
CMitsiadesLab retweeted
31 May 2023
Very proud to share latest work from Constantine Mitsiades lab, started during my time at @DanaFarber / @harvardmed .
nature.com/articles/s43018-0…
2
3
13
1,059
CMitsiadesLab retweeted
26 May 2023
A new study published in @NatureCancer led by @CMitsiadesLab at @danafarber uses CRISPR to identify more than 100 genes as potential leads for the discovery of new drugs for multiple myeloma.
Full release ➡️ ms.spr.ly/6010gjNMg
#mmsm #myeloma #CRISPR
3
12
4,131
26 May 2023
New paper by our lab & collaborators published in @NatureCancer
Genome-scale functional genomics identify genes preferentially essential for multiple myeloma cells compared to other neoplasias
nature.com/articles/s43018-0…
#mmsm #myeloma #CRISPR @DanaFarber @broadinstitute
1
19
46
15,294
26 May 2023
Many thanks to all coauthors from @DanaFarber, @broadinstitute, @harvardmed, @WinshipAtEmory, @ufhealthcancer, @theMMRF (@AuclairDan, @joanbethlevy), @MedicineAtUL (@AedinCulhane), @TGen (@PedalheadPHX), @CancerCenterAms (Richard Groen)
1
3
269
26 May 2023
Stay tuned for a “tweetorial” describing the main findings and key implications of the study!
1
201
CMitsiadesLab retweeted
23 Aug 2022
Excited to share our new work on NK cells. Fantastic work by @ollidufva & @DrSGandalf, team members from our lab @HelsinkiUniMed & @CMitsiadesLab @DanaFarberNews and many collaborators. Fascinating to see how different cancer cells impact NK cell responses biorxiv.org/content/10.1101/…
7
17
CMitsiadesLab retweeted
23 Aug 2022
We finally tested how knocking out CRISPR hits in cancer cells influences NK cells. This gave some interesting results, such as defective activation with CD58 knockout and increased activation with JAK1 knockout.
18/
1
1
2
CMitsiadesLab retweeted
23 Aug 2022
Many perturbations had strong transcriptomic effects as seen from the UMAPs. Several of them also affected the IFNy negative feedback response to NK attack, giving clues to how they mediate NK resistance/sensitivity. Also many more interesting downstream effects in the paper
17/
1
1
5
CMitsiadesLab retweeted
23 Aug 2022
We analyzed the transcriptomic effects of knocking out or activating 65 hits in cancer cells both in the resting state and under NK attack.
16/
1
1
1
CMitsiadesLab retweeted
23 Aug 2022
We wondered which of the CRISPR hits could explain variation and correlate with sensitivity to NK cells across the PRISM cell lines in their expression levels. Turns out these include activating receptor ligands (NCR3LG1, ULBP1, PVR) and MHC-I.
13/
1
2
2